Synlogic (NASDAQ: SYBX) reported Q4 EPS of ($0.37), $0.07 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $520 thousand.

"We have built key Synthetic Biotic platform capabilities in synthetic biology, manufacturing and development to enable the efficient generation of therapeutics that have the potential to address unmet medical need in a range of indications from rare metabolic diseases to cancer," said Aoife Brennan, M.B., Ch.B., Synlogic's president and chief executive officer. "Building on our experience in our PKU program we have made steady progress on new programs in enteric hyperoxaluria and maple syrup urine disease and we look forward to providing more detail on these initiatives as well as the underlying engine that powers our pipeline as year progresses."

For earnings history and earnings-related data on Synlogic (SYBX) click here.